• EU drug regulator’s CHMP backed Enhertu with pertuzumab for first-line HER2-positive metastatic breast cancer, clearing the file for European Commission review.
• Recommendation followed DESTINY-Breast09 data showing a 44% lower risk of progression or death versus THP; median PFS 40.7 months versus 26.9 months.
• If cleared, the regimen would be the first new EU first-line option in more than a decade for this setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607240700BIZWIRE_USPR_____20260723_BW402930) on July 24, 2026, and is solely responsible for the information contained therein.